Top drug regulators from across the globe are expected to meet the Indian drug manufacturers and regulators in Mumbai to discuss and deliberate over export potential of the country, while addressing the regulatory issues affecting exports. This initiative is being taken by the Pharmaceuticals Export Promotion Council of India (Pharmexcil) in association with Indian Drug Manufacturers Association (IDMA) to woo the international buyers and oversees regulators for exploiting new business ventures with the Indian drug exporters.
Thus, to develop a better understanding of the regulatory requirements essential for boosting exports, top regulators from the overseas market will be meeting the Indian counterparts and the drug exporters on April 25 in Mumbai during iPHEX 2013 exposition. Indian manufacturers exporting to overseas market will be given an exclusive opportunity to interact with the overseas regulators so as to pave way for a symbiotic and strategic business relation in future which is in accordance with the regulatory norms of the importing countries.
Apart from that, Pharmexcil is also planning to organise a separate high profile interaction between the stake holders and the region based oversees regulators from the CIS and other Latin American markets for exploring new business avenues in the future on the same day.
According to Dr PV Appaji, director general, Pharmexcil, through this interactive session which will also include a panel discussion, top focus will be given on addressing the queries and doubts that the Indian exporters face while exporting to the regulated as well unregulated markets.
He stressed that by arranging this meeting their main aim is to help the exporters to get a better clarity on the regulatory requirements of the importing countries while ensuring that the oversees regulators are also well aware and confident about the role of the Indian drug manufacturers in providing high quality affordable medicines to the patients across the globe.
“There are lot of issues that Indian exporters are grappling with when it comes to region wise exports, thus through iPHEX we are providing them a perfect avenue to voice their concerns to the international regulators under the same roof. Further there are more than nine Indian drug controllers from top pharma hubs of the country coming for this meeting along with the DCGI, which will help in presenting a better perspective of the Indian drug regulatory system to the industry,” Dr Appaji added.
He further informed that in strategic approach towards developing a strong business relation with the overseas regulators, the Council is also considering the possibility of arranging a plant visit to manufacturing facilities of the Indian companies as per the availability of the regulators following iPHEX.